Market Intelligence, Clinical Progress, and High-Purity Reagents for Multiple Myeloma Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GPRC5D drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GPRC5D ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View GPRC5D Products |
| Gene Delivery | GPRC5D Full-Length ORF Lentivirus Full-length ORF for stable cell line construction preserving native conformation and signaling. Ideal for functional screening (Flow Cytometry ready). |
View GPRC5D Products |
| Benchmark Ab | Anti-GPRC5D (Sequence of Talquetamab) Recombinant positive control for binding and assay standardization. |
View GPRC5D Products |
| Validator | GPRC5D siRNA Set For knockdown verification and specificity confirmation in cell-based assays. |
View GPRC5D Products |
| Related Target: BCMA | TNFRSF17 (BCMA) Synergistic pathway for combination therapy and resistance bypass in Multiple Myeloma. |
View BCMA Products |
| Related Target: CD38 | CD38 Established baseline target for combination therapies in Multiple Myeloma. |
View CD38 Products |
| Related Target: CD3E | CD3E (T-cell Surface Glycoprotein) Co-target for bispecific T-cell engager mechanism validation and T-cell activation assays. |
View CD3E Products |
| Related Target: FCRL5 | FCRL5 (FcRH5) Alternative MM surface antigen; dual-targeting strategy partner. |
View FCRL5 Products |
| Related Target: GPRC5A | GPRC5A (Retinoic Acid-Inducible Orphan GPCR) Subfamily counter-screening to ensure specificity against hair follicle off-targets. |
View GPRC5A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Multi-pass Membrane Conformation & Full-length Integrity | Premade Lentivirus particles encoding full-length GPRC5D; stable cell lines in HEK293 for flow cytometry and native conformation screening. Native glycosylation confirmed by mass spectrometry. |
| Cross-species PK/PD and Safety Evaluation (Cyno, Mouse) | Human, Cynomolgus, and Mouse GPRC5D ECD-Fc ortholog proteins; Sequence Verified; >95% purity; Endotoxin <1 EU/µg. |
| GPRC5 Subfamily Selectivity (A, B, C) and Off-target Risk | Homologous protein panel (GPRC5A, GPRC5B, GPRC5C) for stringent counter-screening by SPR/ELISA; mass spectrometry verified. |
| Hair Follicle Toxicity Screening (Epitope Mapping) | Epitope-mapped reference antibodies (Talquetamab sequence) to validate binding regions distinct from follicular GPRC5A epitopes. |
| BCMA/GPRC5D Dual-targeting Assays | Co-expression lentivirus systems (GPRC5D + TNFRSF17) for combination therapy validation. |
| Internalization Efficiency for ADC Payload Delivery | Full-length lentivirus-transduced cells suitable for pH-sensitive dye internalization assays and confocal validation. |
| Lack of Positive Controls & False-Positive Binding | Anti-GPRC5D benchmark antibody (Talquetamab sequence) and validated siRNA for knockdown specificity confirmation. |
Live GPRC5D R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GPRC5D therapeutics has intensified following the FDA approval of talquetamab (Janssen/Genmab), marking a pivotal shift from traditional mAbs and chemotherapy to immunotherapy modalities. As first-generation bispecific T-cell engagers reach the clinic and demonstrate efficacy in BCMA-refractory populations, the next wave of R&D is targeting combination regimens and dual-antigen targeting (e.g., GPRC5D x BCMA) to bypass antigen escape mechanisms. Major players including Janssen, Bristol Myers Squibb, Roche, and multiple biotechs are advancing bispecific T-cell engagers, CAR-T therapies, and ADCs. The restricted normal tissue expression profile of GPRC5D (limited to hair follicles, hard palate, and keratinized epithelium) continues to validate its position as a premier multiple myeloma target, driving demand for conformationally accurate reagents that can distinguish tumor-selective epitopes from on-target off-tumor cross-reactivity.
Key Genetic Variant
A known single nucleotide variant in the GPRC5D gene is documented in dbSNP as rs3741822 (UniProt VAR_018297). This nonsynonymous substitution may influence receptor structure and should be considered in epitope design and patient stratification studies. TarMart offers custom mutant protein and cell line services to evaluate the impact of this variant on drug binding.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Bispecific TCE (GPRC5D x CD3) | Janssen (Talquetamab), Roche, BMS | Relapsed/Refractory Multiple Myeloma (RRMM) | Cell-based binding on full-length GPRC5D (Lentivirus stable cells) for accurate immune synapse formation; T-cell activation assays. |
| CAR-T Cell Therapy | BMS (CC-95266), Autolus, Legend Biotech | RRMM, BCMA-experienced | Flow cytometry validation using sequence-verified benchmark antibody; high-titer lentivirus for consistent GPRC5D surface expression density. |
| ADC | Pfizer, Various Preclinical | Multiple Myeloma | Internalization assay on native conformation cell lines (pH-sensitive dye, confocal); high-purity ECD for SPR binding kinetics. |
| Combination / Sequential | Industry-wide | Multiple Myeloma | Multi-target panels (BCMA, FCRL5, CD38) for combination screening; co-expression lentivirus for dual-target validation. |
Molecular Differentiation & Assay Strategy
To develop best-in-class GPRC5D therapeutics, several molecular attributes require optimization with corresponding assay solutions:
- Affinity (nM range): Not too high to avoid excessive off-tumor toxicity. Use SPR/BLI for affinity ranking (human/cyno/mouse ECD-Fc proteins).
- Safety: Screen against GPRC5 family members (A, B, C) using homologous protein panels. Include epitope mapping with Talquetamab benchmark to identify tumor-selective epitopes.
- Internalization (for ADC): Quantify uptake kinetics using lentivirus-transduced stable cells with pH-sensitive dyes.
- Dual-targeting (BCMA/GPRC5D): Co-expression lentivirus for combination therapy validation.
These assays are directly supported by TarMart’s reagent ecosystem.